TSVT Projected Dividend Yield
2seventy bio Inc ( NASDAQ : TSVT )2seventy bio is a cell and gene therapy company focused on the research, development, and commercialization of treatments for cancer. Co. develops chimeric antigen receptor (CAR) T cell therapy for multiple myeloma. Co. is developing various clinical programs, including DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma, as well as preclinical programs, including bbT4015, a CAR T cell therapy targeting MUC16. Additionally, Co. is developing ABECMA for the treatment of adults with multiple myeloma who have received at least four prior lines of therapy. 21 YEAR PERFORMANCE RESULTS |
TSVT Dividend History Detail TSVT Dividend News TSVT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |